well
known
mucos
tissu
contain
largest
surfac
area
human
bodi
front
line
natur
host
defens
variou
pathogen
fact
infecti
diseas
pathogen
probabl
gain
entri
suscept
human
host
open
mucos
surfac
human
immunodefici
viru
type
one
mainli
sexual
transmit
viru
also
primarili
target
vagin
gastrointestin
mucosa
entri
site
viral
transmiss
seed
replic
amplif
sinc
establish
earli
replic
vagin
rectal
mucos
tissu
induct
suffici
mucos
immun
initi
site
transmiss
becom
essenti
protect
vaccin
howev
despit
fact
current
convent
vaccin
strategi
remain
unsuccess
prevent
infect
suffici
financi
support
resourc
yet
given
develop
vaccin
abl
elicit
protect
mucos
immun
sexual
transmiss
interestingli
chines
ancestor
invent
variol
intranas
administr
one
thousand
year
ago
led
discoveri
success
smallpox
vaccin
final
erad
diseas
hope
mankind
develop
mucos
aid
vaccin
ultim
help
control
aid
pandem
order
discov
effect
mucos
aid
vaccin
necessari
deep
understand
mucos
immunolog
test
variou
mucos
vaccin
strategi
virus
mucos
membran
contain
largest
surfac
area
human
bodi
provid
protect
variou
bodi
caviti
expos
extern
environ
intern
organ
mucos
membran
compris
line
gastrointestin
urogenit
respiratori
tract
actual
portal
entri
infecti
diseas
pathogen
first
line
defens
host
protect
infect
variou
mechan
includ
physic
barrier
mechan
discharg
chemic
degrad
innat
immun
special
mucos
immun
respons
mucos
tissu
repres
critic
immunolog
repertoir
compartment
independ
system
immun
organ
mucos
tissu
healthi
human
bodi
compris
much
lymphocyt
may
transfer
variou
mucosalassoci
lymphoid
tissu
malt
blymphocyt
malt
mainli
produc
secretori
iga
siga
releas
coval
link
dimer
uniqu
structur
make
siga
stabl
resist
mani
kind
digest
enzym
siga
consid
major
protect
immunoglobulin
mucos
surfac
lymphocyt
hand
either
act
cytotox
lymphocyt
ctl
eg
cell
help
induct
cellular
mediat
immun
antibodi
respons
eg
cell
upon
encount
foreign
antigen
activ
b
cell
may
migrat
induct
site
eg
peyer
patch
gut
nasopharynxassoci
lymphoid
tissu
nalt
oropharyng
caviti
travel
lymph
node
peripher
circul
back
home
effector
site
eg
lamina
propria
intestin
respiratori
tract
glandular
tissu
result
gener
antigenspecif
helper
celldepend
iga
respons
helper
celland
ctldepend
immun
respons
function
front
line
defens
mucos
surfac
home
behavior
cell
mainli
attribut
upregul
express
sitespecif
adhes
molecul
cytokin
receptor
guid
cell
back
mucosa
recognit
mucos
tissuespecif
receptor
vascular
endotheli
cell
critic
mucos
induct
site
stand
sentinel
intestin
respiratori
system
repres
major
site
mucos
immun
respons
initi
human
immunodefici
viru
type
one
caus
agent
acquir
immunodefici
syndrom
aid
mainli
sexual
transmit
viru
primarili
target
gastrointestin
vagin
mucosa
entri
site
viral
transmiss
seed
replic
amplif
sinc
establish
earli
replic
vagin
rectal
mucos
tissu
induct
suffici
mucos
immun
initi
site
transmiss
becom
essenti
protect
vaccin
provid
overview
develop
aid
mucos
vaccin
perspect
mucos
vaccin
candid
vaccin
biolog
prepar
induc
immun
particular
diseas
term
vaccin
deriv
edward
jenner
use
term
cowpox
latin
variola
vaccina
adapt
latin
vacca
cow
edward
jenner
demonstr
cowpox
administ
human
provid
protect
smallpox
histori
use
biolog
prepar
prevent
smallpox
howev
trace
back
northern
song
dynasti
ad
chines
ancestor
collect
scab
skin
lesion
smallpox
patient
use
ground
particl
prevent
new
infect
procedur
call
variol
interestingli
procedur
involv
deliveri
biolog
prepar
intranas
inocul
common
rout
modern
mucos
vaccin
techniqu
subsequ
introduc
european
countri
ladi
mari
montagu
prior
later
led
discoveri
vaccin
modern
immunolog
recent
decad
rapid
develop
modern
immunolog
signific
progress
made
understand
structur
function
mucos
immun
system
clear
mucos
vaccin
educ
immun
cell
mucos
induct
site
thu
induc
protect
immun
mucos
system
compart
one
classic
mucos
vaccin
oral
polio
vaccin
opv
liveattenu
strain
spontan
mutat
viral
genom
opv
gener
seri
passag
polio
viru
nonhuman
cell
subphysiolog
temperatur
comparison
inact
polio
vaccin
ipv
given
inject
opv
elicit
neutral
antibodi
prevent
spread
polioviru
nervou
system
also
induc
excel
siga
respons
intestin
mucosa
primari
site
polioviru
entri
replic
contribut
greatli
worldwid
erad
polio
howev
concern
revers
liveattenu
vaccin
virul
form
opv
larg
replac
ipv
develop
countri
anoth
well
known
mucos
vaccin
recent
year
live
attenu
trival
coldadapt
influenza
vaccin
caivt
manufactur
medimmun
inc
flumist
given
gentl
nasal
mist
nasal
vaccin
prove
safe
effect
well
toler
adult
includ
infect
approv
unit
state
sinc
convent
vaccin
proven
success
infect
necessari
explor
strategi
includ
mucos
vaccin
genet
diverg
cousin
simian
immunodefici
viru
siv
use
host
protein
chemokin
receptor
primari
secondari
receptor
moreov
siv
replic
optim
activ
memori
cell
cell
type
abund
mucos
lymph
tissu
first
demonstr
sivmacaqu
model
system
mucos
lymph
tissu
initi
predomin
site
siv
infect
acut
stage
infect
high
viral
load
detect
intestin
mucosa
siv
infect
result
pathogen
effect
indic
deplet
signific
proport
cell
gut
peripher
blood
sinc
stage
similar
effect
found
peripher
lymphoid
tissu
intestin
appear
major
target
siv
replic
major
site
cell
loss
earli
siv
infect
fact
gutassoci
lymph
tissu
contain
total
lymphocyt
similar
find
subsequ
made
macaqu
infect
humansimian
immunodefici
viru
shiv
harbor
envelop
implic
mucos
lymph
tissu
initi
predomin
site
infect
cell
loss
predomin
effect
subcompart
gastrointestin
gi
mucosa
stage
diseas
loss
appear
easili
revers
significantli
greater
cell
loss
gi
mucosa
despit
five
year
fulli
suppress
therapi
sinc
sexual
transmit
establish
initi
replic
mucos
tissu
induct
suffici
mucos
immun
initi
site
transmiss
becom
essenti
develop
protect
vaccin
studi
tri
understand
earli
event
follow
transmiss
siv
via
mucos
surfac
virus
found
replic
predominantli
cell
portal
entri
lymphoid
tissu
virus
found
propag
activ
prolifer
cell
also
rest
cell
rest
cell
persist
antiretrovir
therapi
pose
great
difficulti
attempt
erad
viru
vivo
howev
siv
readili
dissemin
system
circul
rather
local
mucosa
viral
inocul
earli
stage
infect
moreov
mucos
barrier
greatli
limit
infect
cervicovagin
tissu
thu
initi
founder
popul
infect
cell
smaller
recent
find
indic
dramat
evolutionari
bottleneck
occur
heterosexu
infect
appar
initi
singl
variant
transmit
new
recipi
initi
small
founder
popul
depend
continu
seed
establish
product
infect
system
lymph
tissu
defin
small
window
maximum
vulner
viru
opportun
host
vaccin
intervent
prevent
control
infect
deplet
memori
cell
especi
gut
acut
phase
infect
provid
evid
induct
mucos
immun
consid
high
prioriti
develop
vaccin
mucos
transmit
find
provid
support
evid
strategi
focus
mucos
vaccin
induc
protect
immun
site
viral
transmiss
one
critic
bottleneck
develop
effect
vaccin
current
inabl
induc
local
mucos
immun
durabl
high
level
antibodi
respons
high
frequenc
cellular
immun
respons
human
mucos
siga
consid
import
role
prevent
transmiss
sexual
intercours
sever
studi
evalu
neutral
activ
siga
purifi
plasma
mucos
sampl
highli
expos
persist
seroneg
individu
hepsi
infect
peopl
primari
isol
differ
viral
clade
phenotyp
specif
neutral
activ
purifi
iga
cervicovagin
fluid
found
major
sampl
contrast
cervicovagin
fluid
lowrisk
uninfect
hivseroneg
individu
lack
neutral
iga
moreov
mucos
iga
deriv
highli
expos
seroneg
individu
abl
block
epitheli
transcytosi
neutral
cell
infect
howev
analyz
group
expos
uninfect
femal
commerci
sex
worker
gambia
signific
vagin
siga
igg
respons
detect
none
vagin
secret
test
display
neutral
activ
sinc
studi
seem
controversi
becom
necessari
studi
neutral
iga
igg
induc
mucos
vaccin
interestingli
recent
studi
indic
igg
iga
might
contribut
protect
sexual
transmiss
among
expos
seroneg
peopl
known
mucos
polymer
iga
play
predomin
role
protect
influenza
virusinduc
patholog
upper
respiratori
tract
whether
similar
effect
achiev
remain
unknown
evid
function
polymer
igalik
switch
iga
isotyp
stronger
impact
protect
potenti
two
antibodi
could
interfer
entri
across
mucos
epitheli
layer
vitro
find
indic
although
siga
major
humor
defens
mechan
mucos
surfac
wise
induc
local
produc
igm
igg
well
serumderiv
igg
via
mucos
vaccin
mucos
neutral
igg
also
import
protect
macaqu
repeat
intravagin
exposur
low
dose
shiv
use
coreceptor
demonstr
sivmacaqu
model
cytotox
lymphocyt
ctl
play
crucial
role
suppress
siv
replic
vivo
acut
chronic
infect
fact
base
mathemat
model
suggest
first
cell
respons
transmittedfound
virus
human
earli
contribut
initi
declin
plasma
viru
acut
infect
besid
mucos
antibodi
respons
high
frequenc
mucos
cellular
immun
respons
detect
essenti
prevent
local
product
infect
elimin
initi
founder
popul
infect
cell
cell
respons
found
genit
mucosa
sex
worker
absenc
detect
infect
suggest
protect
role
cellmedi
immun
moreov
cellular
immun
respons
especi
mediat
ctl
helper
lymphocyt
need
control
siv
mucos
tissu
particular
magnitud
time
establish
excess
effector
cell
versu
target
found
correl
extent
control
siv
infect
outcom
therefor
vaccin
capabl
induc
high
frequenc
broadli
reactiv
cellmedi
respons
consid
critic
control
spread
viru
although
multipl
approach
develop
induc
mucos
ctl
respons
ctl
weak
low
frequenc
could
complet
prevent
initi
viral
replic
dissemin
develop
effect
mucos
vaccin
besid
immunogen
design
three
factor
consid
vector
antigen
deliveri
adjuv
enhanc
mucos
immun
respons
rout
immun
induc
mucos
system
immun
respons
earli
possibl
select
proper
antigen
deliveri
vector
necessari
induct
effici
mucos
immun
respons
studi
macaqu
found
immun
live
attenu
siv
vaccin
induc
specif
local
ctl
mucosa
dramat
reduc
viremia
mucos
challeng
siv
sinc
live
attenu
riski
use
human
vaccin
viral
vector
investig
stimul
mucos
immun
live
attenu
vesicular
stomat
viru
nonrepl
adenoviru
vaccinia
viru
includ
modifi
vaccinia
ankara
mva
vector
venezuelan
equin
enceph
viru
vee
end
vaccinia
viral
vector
probabl
one
intens
studi
live
recombin
vector
sever
studi
demonstr
abil
vacciniabas
vaccin
induc
mucos
immun
respons
infecti
pathogen
exampl
either
mucos
system
rout
immun
live
attenu
vaccinia
nyvacsivgp
recombin
vaccin
result
gagspecif
tcell
respons
mucos
tissu
macaqu
furthermor
vaccin
base
mva
vector
effect
induc
protect
respons
differ
respiratori
virus
sarscov
influenza
respiratori
syncyti
viru
follow
immun
via
mucos
rout
intranas
inocul
mvabas
vaccin
name
mvahiv
immunogen
wherea
intravagin
rout
disappoint
sinc
mucos
immunogen
mvahiv
low
new
approach
need
improv
poxviru
vector
system
sever
approach
evalu
anim
first
intranas
codeliveri
mvahiv
plu
adjuv
cholera
toxin
ct
significantli
enhanc
cellular
humor
immun
respons
antigen
mucos
surfac
vaccin
mice
due
limit
ct
human
use
cytokin
gmcsf
evalu
substitut
induct
system
mucos
ctl
nasal
immun
thu
function
activ
candid
adjuv
need
test
context
mvahiv
second
heterolog
dnahiv
primemvahiv
boost
intranas
immun
togeth
ct
produc
cellular
immun
respons
mous
spleen
superior
absenc
ct
moreov
studi
use
rhesu
macaqu
intranas
heterolog
vaccin
shivdna
plu
dna
rmva
induc
systemat
mucos
immun
protect
anim
diseas
progress
intrarect
challeng
pathogen
separ
studi
rhesu
macaqu
vaccin
intrarect
dna
construct
produc
replicationdefect
shiv
particl
boost
rmvashiv
produc
virusspecif
mucos
system
humor
iga
cellmedi
immun
respons
mucos
vaccin
regimen
also
suffici
delay
progress
aid
although
find
promis
seem
limit
advantag
vaccin
via
mucos
rout
comparison
nonmucos
rout
vaccin
exampl
intramuscular
inocul
heterolog
dnamva
vaccin
regimen
show
similar
level
protect
monkey
remain
unknown
whether
much
better
protect
could
achiev
vaccinia
vector
system
optim
stimul
host
mucos
immun
respons
varieti
novel
biolog
vehicl
studi
deliveri
antigen
includ
inert
system
live
recombin
vector
system
inert
system
involv
direct
incorpor
antigen
vehicl
order
increas
immunogen
protect
degrad
enhanc
uptak
mucos
surfac
commonli
use
inert
vector
includ
liposom
immunostimul
complex
iscom
lactic
acid
lectin
vector
howev
still
earli
stage
preclin
studi
sinc
vector
easili
manipul
vitro
target
deliveri
antigen
antigen
present
cell
apc
might
help
improv
immunogen
mucos
vaccin
type
live
recombin
vector
system
number
studi
carri
use
bacteri
vector
encod
antigen
phase
studi
safeti
immunogen
oral
attenu
salmonella
enterica
serovar
typhimurium
deliv
gag
antigen
via
salmonella
type
iii
secret
system
investig
among
healthi
volunt
although
subject
mucos
immun
respons
vector
antigen
respons
specif
gag
low
disappoint
sinc
vaccin
high
dose
group
develop
sever
advers
event
diarrhea
fever
abnorm
transaminas
vaccin
probabl
requir
attenu
laboratori
research
recent
report
novel
replicationcompet
modifi
vaccina
tiantan
mvtt
promis
mucos
vaccin
vector
use
sarscov
spike
glycoprotein
test
antigen
conduct
headtohead
comparison
mva
mvtt
two
vaccin
inocul
mice
via
seven
differ
rout
immun
found
neutral
antibodi
nab
respons
induc
significantli
differ
mvtt
mva
first
intranas
intraor
io
rout
clearli
induc
highest
level
nab
mvtt
mva
second
compar
level
nab
elicit
via
io
immun
mvtt
induc
higher
nab
respons
mva
experi
moreov
increas
inocul
dose
mva
pfumous
observ
signific
improv
nab
respons
mice
via
either
io
rout
contrast
pfu
mvtt
still
abl
induc
signific
level
nab
respons
mice
via
io
rout
therefor
data
indic
mvtt
may
preferenti
target
mucosa
immun
system
signifi
superior
mva
vector
system
studi
evalu
mvtt
mucos
aid
vaccin
use
sivmacaqu
model
although
anim
investig
led
hypothesi
system
vaccin
induc
virusspecif
ctl
mucos
site
remain
plausibl
mucos
vaccin
remain
effect
way
induc
high
longterm
protect
immun
mucos
site
viral
transmiss
includ
increas
effort
understand
mucos
transmiss
greater
attent
drawn
studi
aid
mucos
vaccin
sinc
convent
vaccin
strategi
success
use
aid
necessari
provid
suffici
financi
support
resourc
studi
protect
mucos
immun
new
vaccin
method
sexual
transmiss
till
still
mani
unansw
question
develop
protect
mucos
vaccin
unansw
question
relat
divers
mucos
tissu
role
innat
mucos
immun
lack
understand
immun
correl
mucos
protect
rapid
format
latent
infect
tcell
pool
mucos
reservoir
deplet
cell
especi
gut
stage
infect
absenc
effect
mucos
adjuv
human
use
poor
immunogen
current
envelop
antigen
induc
broadli
neutral
antihiv
antibodi
mucos
surfac
failur
merck
vaccin
call
effort
studi
immunolog
vaccinolog
evid
possibl
identifi
cellmedi
correl
protect
vaccin
regimen
strong
enough
encourag
find
came
recent
studi
heterolog
regimen
elicit
strong
cellmedi
immun
respons
correl
signific
immun
control
pathogen
siv
challeng
end
evalu
variou
heterolog
prime
boost
vaccin
regimen
studi
especi
mucos
rout
vaccin
critic
area
investig
magnitud
time
establish
excess
effector
cell
versu
target
found
essenti
mucos
control
siv
infect
recent
news
us
militari
hiv
research
program
thai
ministri
public
health
indic
primeboost
combin
two
aid
vaccin
candid
shown
partial
efficaci
administ
combin
vaccin
increas
chanc
prevent
infect
shown
phase
iii
efficaci
trial
thailand
intenttotreat
strategi
data
analysi
modifi
data
analyz
base
perprotocol
intenttotreat
analys
differ
drop
result
reach
statist
signific
although
remain
unknown
whether
vaccineinduc
immun
contribut
partial
protect
stage
find
first
demonstr
candid
aid
vaccin
provid
benefit
human
aid
vaccin
research
develop
remain
long
march
order
discov
effect
mucos
aid
vaccin
necessari
deep
understand
mucos
immunolog
test
variou
vaccin
strategi
includ
mucos
vaccin
follow
fundament
rule
host
natur
defens
